View of A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Guselkumab at 52 weeks for the Treatment of Psoriatic Arthritis

Return to Article Details A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Guselkumab at 52 weeks for the Treatment of Psoriatic Arthritis Download Download PDF